AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil
Number of subjects: 124
Study 2530925 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 124
Study 78150 — intervention group
Group type: EXPERIMENTAL
Intervention: metiamide
Number of subjects: 68
Study 78150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 30851458 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 80
Study 30851458 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study 28632487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine plus idarubicin (AI)
Number of subjects: 299
Study 28632487 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine plus high-dose daunorubicin (AD)
Number of subjects: 299
Study 28632487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine plus idarubicin (AI) in patients with FLT3 ITD mutation
Number of subjects: 299
Study 28632487 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine plus high-dose daunorubicin (AD) in patients with FLT3 ITD mutation
Number of subjects: 299
Study 25580869 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 393
Study 25580869 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 393
Study 24019048 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention of jejunal mucosa (Group A)
Number of subjects: 46
Study 24019048 — intervention group
Group type: COMPARATOR
Intervention: Removal of jejunal mucosa (Group B)
Number of subjects: 46
Study 21624655 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide/timolol
Number of subjects: 25
Study 21624655 — intervention group
Group type: COMPARATOR
Intervention: brinzolamide/timolol
Number of subjects: 25
Study 19796205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite extracts
Number of subjects: 194
Study 16500336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E with conjugated equine estrogen (CEE) (0.625 mg)
Number of subjects: 75
Study 16500336 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg)
Number of subjects: 75
Study 16500336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16500336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 75
Study 15849968 — intervention group
Group type: EXPERIMENTAL
Intervention: VIMANG for 6 months
Number of subjects: 68
Study 15849968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10955327 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg bid (n = 1,099)
Number of subjects: 5000
Study 10955327 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 50 mg bid (n = 690)
Number of subjects: 5000
Study 10955327 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 100 mg bid (n = 1,131)
Number of subjects: 5000
Study 10955327 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg bid (n = 1,125)
Number of subjects: 5000
Study 10955327 — intervention group
Group type: EXPERIMENTAL
Intervention: celecoxib 400 mg bid (n = 434)
Number of subjects: 5000
Study 10955327 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 1,136)
Number of subjects: 5000
Study 8968014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chlorthalidone (12.5-25.0 mg/d) with step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)
Number of subjects: 4736
Study 8968014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 1316075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg once daily)
Number of subjects: 727
Study 1316075 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 727
Study 2991475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH)
Number of subjects: 119
Study 2991475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVH)
Number of subjects: 119
Study 29901417 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + supplement (ES) group
Number of subjects: 32
Study 29901417 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + placebo (EP) group
Number of subjects: 32
Study 29901417 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement (S) group
Number of subjects: 32
Study 29901417 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 32
Study 28117244 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access during coronary angiography (CA)
Number of subjects: 21675
Study 28117244 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access during percutaneous coronary intervention (PCI)
Number of subjects: 21675
Study 28117244 — intervention group
Group type: COMPARATOR
Intervention: Femoral access during coronary angiography (CA)
Number of subjects: 21675
Study 28117244 — intervention group
Group type: COMPARATOR
Intervention: Femoral access during percutaneous coronary intervention (PCI)
Number of subjects: 21675
Study 26335787 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotics plus pidotimod (PDT)
Number of subjects: 20
Study 26335787 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotics alone
Number of subjects: 20
Study 23219519 — intervention group
Group type: EXPERIMENTAL
Intervention: BioXcell (CS)
Number of subjects: 524
Study 23219519 — intervention group
Group type: EXPERIMENTAL
Intervention: BioXcell (FT)
Number of subjects: 524
Study 23219519 — intervention group
Group type: COMPARATOR
Intervention: AndroMed (CS)
Number of subjects: 524
Study 23219519 — intervention group
Group type: COMPARATOR
Intervention: AndroMed (FT)
Number of subjects: 524
Study 23219519 — intervention group
Group type: COMPARATOR
Intervention: AndroMed (young rams)
Number of subjects: 524
Study 23219519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (intracervical AI)
Number of subjects: 524
Study 23219519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (intrauterine AI)
Number of subjects: 524
Study 21538780 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH bandage
Number of subjects: 112
Study 21538780 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 112
Study 18496296 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily (n=27)
Number of subjects: 50
Study 18496296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily (n=28)
Number of subjects: 50
Study 16796157 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-osmolarity ORS solution (245 mmol/L)
Number of subjects: 176
Study 16796157 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO-ORS solution (311 mmol/L)
Number of subjects: 176
Study 16796157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 176
Study 12657118 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus radiation therapy
Number of subjects: 74
Study 12657118 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 74
Study 11048902 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 25 mg orally once daily for 18 weeks)
Number of subjects: 48
Study 9072308 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron
Number of subjects: 307
Study 9072308 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron
Number of subjects: 307
Study 9072308 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron
Number of subjects: 307
Study 9072308 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron
Number of subjects: 307
Study 9072308 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of dolasetron
Number of subjects: 307
Study 8471122 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 3089576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 7
Study 3089576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer absorbable suture
Number of subjects: 24
Study 31724764 — intervention group
Group type: COMPARATOR
Intervention: Single-layer absorbable suture
Number of subjects: 24
Study 31724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional barbed suture
Number of subjects: 24
Study 31724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional barbed suture
Number of subjects: 24
Study 31724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer unidirectional barbed suture
Number of subjects: 24
Study 31724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer bidirectional barbed suture
Number of subjects: 24
Study 29859385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus omega-3 fatty acid (2000 mg/day)
Number of subjects: 60
Study 27291883 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine
Number of subjects: 18
Study 24420547 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 U oral vitamin D3 every 2 months
Number of subjects: 68
Study 24420547 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 68
Study 23319503 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour physician-targeted interactive educational session and patient information handout
Number of subjects: 256
Study 23319503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 256
Study 23319503 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour physician-targeted interactive educational session
Number of subjects: 256
Study 23319503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 256
Study 21427901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrozoline hydrochloride
Number of subjects: 30
Study 21427901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 30
Study 21427901 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride
Number of subjects: 30
Study 21427901 — intervention group
Group type: EXPERIMENTAL
Intervention: AlCl3
Number of subjects: 30
Study 21427901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe2(SO4)3
Number of subjects: 30
Study 21427901 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 18047578 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge training and counselling provided by a researcher
Number of subjects: 109
Study 18047578 — intervention group
Group type: COMPARATOR
Intervention: Routines provided by a nurse (Control)
Number of subjects: 109
Study 16928483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 3099
Study 16928483 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3099
Study 14585251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group A)
Number of subjects: 96
Study 14585251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group B)
Number of subjects: 96
Study 14585251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group C)
Number of subjects: 96
Study 14585251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50mg
Number of subjects: 96
Study 14585251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11130154 — intervention group
Group type: EXPERIMENTAL
Intervention: Own brand of smokeless tobacco
Number of subjects: 0
Study 11130154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free smokeless tobacco
Number of subjects: 0
Study 11130154 — intervention group
Group type: COMPARATOR
Intervention: No smokeless tobacco (abstinence)
Number of subjects: 0
Study 9181760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood hyperviscosity
Number of subjects: 23
Study 9181760 — intervention group
Group type: COMPARATOR
Intervention: Normal cord blood viscosity
Number of subjects: 23
Study 9181760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood hyperviscosity (not polycythemic)
Number of subjects: 23
Study 8266016 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulglycotide three times daily (n = 50)
Number of subjects: 100
Study 8266016 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo (n = 50)
Number of subjects: 100
Study 2885185 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 60
Study 2885185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 60
Study 2885185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 60
Study 29705454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (12 weeks, 1 time/week, 45 min)
Number of subjects: 44
Study 29705454 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 44
Study 27086046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Incisal Nerve Block (MINB) with 2 mL 2% lidocaine with 1:200,000 epinephrine and a mock IANB with 2 mL sterile saline
Number of subjects: 153
Study 27086046 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block (IANB) with 2 mL 2% lidocaine
Number of subjects: 153
Study 27086046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MINB and IANB with 2 mL each of 2% lidocaine
Number of subjects: 153
Study 25065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 12 sessions over 4.5 months) with standard care
Number of subjects: 110
Study 25065535 — intervention group
Group type: EXPERIMENTAL
Intervention: Long motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 24 sessions over 9 months) with standard care
Number of subjects: 110
Study 25065535 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 110
Study 22475399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine PLGA
Number of subjects: 19
Study 22475399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine PLGA
Number of subjects: 19
Study 22475399 — intervention group
Group type: COMPARATOR
Intervention: Placebo PLGA
Number of subjects: 19
Study 22475399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil PLGA
Number of subjects: 19
Study 20163375 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg daily
Number of subjects: 1798
Study 20163375 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg b.d.
Number of subjects: 1798
Study 20163375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1798
Study 20163375 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride (both dosages)
Number of subjects: 1798
Study 20163375 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride
Number of subjects: 1798
Study 17453011 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) program combined with neuromotor rehabilitation
Number of subjects: 36
Study 17453011 — intervention group
Group type: COMPARATOR
Intervention: Neuromotor rehabilitation only (Control)
Number of subjects: 36
Study 20821896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer program for poor mothers
Number of subjects: 0
Study 19810295 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 30
Study 19810295 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 30
Study 12186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal renal function (creatinine clearance <70 mL/min) in the STE group
Number of subjects: 18621
Study 12186803 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal renal function (creatinine clearance <70 mL/min) in the NSE group
Number of subjects: 18621
Study 12186803 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance
Number of subjects: 18621
Study 9721959 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 89
Study 9721959 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav plus aminoglycoside
Number of subjects: 89
Study 7992239 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fish (250 g daily for six weeks)
Number of subjects: 32
Study 7992239 — intervention group
Group type: COMPARATOR
Intervention: Control group (bread enriched with selenium or normal diet)
Number of subjects: 32
Study 2538300 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet rich in fibres (70 g/day)
Number of subjects: 12
Study 2538300 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet enriched by guar (9 g of guar added to 30 g of natural fibres/day)
Number of subjects: 12
Study 31393809 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 29
Study 29122523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg of a 20% SCIg solution (IgPro20) weekly
Number of subjects: 172
Study 29122523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg of a 20% SCIg solution (IgPro20) weekly
Number of subjects: 172
Study 29122523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2% human albumin solution)
Number of subjects: 172
Study 29122523 — intervention group
Group type: COMPARATOR
Intervention: 0.2 g/kg SCIg vs Placebo
Number of subjects: 172
Study 29122523 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g/kg SCIg vs Placebo
Number of subjects: 172
Study 29122523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg SCIg vs 0.2 g/kg SCIg
Number of subjects: 172
Study 29122523 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally related adverse events
Number of subjects: 172
Study 29122523 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 172
Study 27633186 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (0.5 mg or 1.0 mg)
Number of subjects: 3297
Study 27633186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3297
Study 27633186 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3297
Study 25523957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Mint ListerineR (MWa)
Number of subjects: 0
Study 25523957 — intervention group
Group type: EXPERIMENTAL
Intervention: Periobacter R (MWb)
Number of subjects: 0
Study 23153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated school uniforms (impregnated with permethrin)
Number of subjects: 2000
Study 23153360 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard school uniforms without insecticide treatment)
Number of subjects: 2000
Study 21142442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy including lopinavir/ritonavir
Number of subjects: 0
Study 21142442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 21142442 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of interferon in plasma of AIDS patients
Number of subjects: 0
Study 17484706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) in the form of commercially available yoghurt, 100 g daily for 4 weeks
Number of subjects: 27
Study 17484706 — intervention group
Group type: COMPARATOR
Intervention: Standard pasteurised yoghurt (control group)
Number of subjects: 27
Study 16424955 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional electrosurgery
Number of subjects: 38
Study 16424955 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled bipolar electrosurgery
Number of subjects: 38
Study 16424955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic shears (Harmonic Scalpel)
Number of subjects: 38
Study 16424955 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 38
Study 14764410 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per os daily for 120 days)
Number of subjects: 200
Study 14764410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 120 days, followed by 60 days of only placebo)
Number of subjects: 200
Study 10533328 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (Group A)
Number of subjects: 50
Study 10533328 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium (Group B)
Number of subjects: 50
Study 8615544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure sodium discharge lamp with improved coefficiency of transmitting the colours (HPSM)
Number of subjects: 63
Study 8615544 — intervention group
Group type: COMPARATOR
Intervention: Filament lamps (GL)
Number of subjects: 63
Study 8615544 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium discharge lamp (HPS)
Number of subjects: 63
Study 2344897 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (1200 mg/die)
Number of subjects: 115
Study 2344897 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (240 mg/die)
Number of subjects: 115
Study 6108724 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined timothy pollen extract (R)
Number of subjects: 36
Study 6108724 — intervention group
Group type: COMPARATOR
Intervention: Whole timothy pollen extract (W)
Number of subjects: 36
Study 6108724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 31986897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 74
Study 31986897 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 74
Study 31488353 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed coronary intervention (22.7 hours)
Number of subjects: 142
Study 31488353 — intervention group
Group type: COMPARATOR
Intervention: Immediate coronary intervention (0.4 hours)
Number of subjects: 142
Study 31488353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Delayed and Immediate)
Number of subjects: 142
Study 29231159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet-joint injections with steroids
Number of subjects: 9
Study 29231159 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 9